ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "tocilizumab and tofacitinib"

  • Abstract Number: 2803 • 2014 ACR/ARHP Annual Meeting

    Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell–Based BioMAP® Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes?

    Alison O'Mahony1, Ellen L. Berg1, Xitong Li1, Markus R. John2, Kandeepan Ganeshalingam2 and Ernest H. Choy3, 1BioSeek, South San Francisco, CA, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Cardiff University, Cardiff, United Kingdom

    Background/Purpose: A number of trials have shown that adding MTX benefits some, but not all, biologics and small molecules to treat RA. Specifically, though treatment…
  • Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting

    Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis

    Stacey Chang1, Laura Sawyer1 and Fred Dejonckheere2, 1Symmetron Limited, London, United Kingdom, 2F. Hoffmann-La Roche, Basel, Switzerland

    Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
  • Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting

    Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments

    Yoshinobu Koyama1, Motohiko Tanino2, Shuji Nagano3, Toshiyuki Ota3 and Toshie Higuchi1, 1Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc., Yokohama, Japan, 3Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan

    Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…
  • Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting

    14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies

    Shintaro Hirata1, Kentaro Hanami2, Anthony Marotta3 and Yoshiya Tanaka4, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 31423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, 4University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences